Search Results

You are looking at 71 - 80 of 96 items for :

  • "dose intensity" x
Clear All
Full access

Adrienne G. Waks and Ann H. Partridge

(intravenous vs oral), schedules, and durations, and although it is clear that greater cumulative dose confers an increased risk of CRA, the impact of administration route and dose intensity/duration on CRA is not known. 14 Although some data suggest that

Full access

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead and Hema Sundar

major consequence of cancer and its treatment in both men and women. 6 , 7 The impact of cancer treatment on fertility is related to patient age at the time of diagnosis and the treatment, and is dependent on the type, duration, and dose intensity of

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

representative of the general older population, because they were probably healthier than most older patients. Many of the treatment regimens used in these trials had lower dose-intensity than those in current use. Nevertheless, these studies are important

Full access

Elizabeth R. Plimack and Gary R. Hudes

and review of the literature . Am J Clin Oncol 2003 ; 26 : 489 - 492 . 48 Rathmell WK Monk JP . High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review . Urology 2008 ; 72 : 659 - 663 . 49

Full access

Elizabeth R. Kessler, Janet B. Kukreja, Christopher L. Geiger and Stacy M. Fischer

Engl J Med 2003 ; 349 : 859 – 866 . 12944571 10.1056/NEJMoa022148 39. Sternberg CN , de Mulder PH , Schornagel JH , . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy

Full access

Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer and Lisa A. Gurski

– 2177 . 23. Sternberg CN de Mulder P Schornagel JH . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours . Eur J Cancer 2006 ; 42 : 50

Full access

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Karl Bernat, Philip J. Bierman, Kristie A. Blum, Robert Chen, Bouthaina Dabaja, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, David G. Maloney, Peter M. Mauch, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Matthew Poppe, Rachel Rabinovitch, Stuart Seropian, Mitchell Smith, Jane N. Winter, Joachim Yahalom, Jennifer Burns, Ndiya Ogba and Hema Sundar

chemotherapy significantly decreases OS rate. 99 Recently, 2 separate studies confirmed that ABVD chemotherapy can be safely administered at the full-dose intensity without any growth factor support. 100 , 101 The NCCN Guidelines do not recommend the routine

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward and Eric P. Winer

relative dose-intensity of chemotherapy. 131 Although the decreased risk for febrile neutropenia was found to be independent of age in this meta-analysis, only the trials involving patients with lymphoma included substantial populations of older

Full access

Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir III, Mary Anne Bergman and Hema Sundar

healthier than most older patients. Many of the treatment regimens used in these trials had lower dose intensity than those in current use. Nevertheless, these studies are important, because they demonstrate that age, by itself, is not a contraindication

Full access

dose intensity [RDI] of ≤80% and ≤85%) between groups. RDI was calculated as the ratio of the delivered dose intensity (total delivered dose divided by the period over which the total dose was measured) to the standard dose intensity as recommended in